iSpecimen Inc.
ISPC- Exchange
- Nasdaq
- Industry
- Services-Commercial Physical & Biological Research
- SEC CIK
- 0001558569
No open-market purchases or sales by iSpecimen Inc. insiders were filed in the last 90 days; 8 institutions reported holding it in 13F filings for Q2 2026, worth $152.0K in total; no superinvestor holds it.
13F holders, Q3 2023
Institutional positions in iSpecimen Inc. as of Sep 30, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 13
- 0 vs. Q2 2023
- Shares held
- 385.2K
- −32.4K (−7.8%) vs. Q2 2023
- Total value
- $238.5K
- −$358.3K (−60.0%) vs. Q2 2023
- New holders
- 4
- 2 more added
- Sold out
- 4
- 4 more reduced
Compare with Q2 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ISPC on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 8 | $152.0K |
| Q1 2026 | 12 | $83.5K |
| Q4 2025 | 11 | $32.9K |
| Q3 2025 | 12 | $443.0K |
| Q2 2025 | 9 | $66.1K |
| Q1 2025 | 8 | $63.7K |
| Q4 2024 | 7 | $94.9K |
| Q3 2024 | 6 | $182.9K |
| Q2 2024 | 13 | $103.1K |
| Q1 2024 | 11 | $69.1K |
| Q4 2023 | 14 | $195.7K |
| Q3 2023 | 13 | $238.5K |
| Q2 2023 | 13 | $596.9K |
| Q1 2023 | 14 | $665.4K |
| Q4 2022 | 13 | $653.0K |
| Q3 2022 | 15 | $781.0K |
| Q2 2022 | 14 | $813.0K |
| Q1 2022 | 13 | $1.98M |
| Q4 2021 | 13 | $9.21M |
| Q3 2021 | 9 | $5.35M |
| Q2 2021 | 7 | $8.10M |
| Q1 2021 | 0 | $0 |
Institutions, Q3 2023
Shares, value and share of portfolio for each institution holding iSpecimen Inc.; share changes are against Q2 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Vanguard Group Inc | 150,600 | $93.4K | 0.00% | −12,304−7.6% | Reduced |
| BlackRock Inc. | 56,699 | $35.2K | 0.00% | 00.0% | Unchanged |
| Grimes & Company, Inc. | 56,189 | $34.8K | 0.00% | −9,400−14.3% | Reduced |
| Geode Capital Management, LLC | 38,498 | $23.9K | 0.00% | +16,902+78.3% | Added |
| Susquehanna International Group, LLP | 22,770 | $14.1K | 0.00% | +22,770 | New |
| Schonfeld Strategic Advisors LLC | 19,500 | $12.1K | 0.00% | −700−3.5% | Reduced |
| Northern Trust Corp | 13,805 | $8.56K | 0.00% | 00.0% | Unchanged |
| HRT Financial LP | 13,380 | $8.00K | 0.00% | +13,380 | New |
| Main Street Financial Solutions, LLC | 10,500 | $6.51K | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 3,117 | $1.93K | 0.00% | +228+7.9% | Added |
| UBS Group AG | 104 | $64 | 0.00% | +104 | New |
| Wells Fargo & Company | 39 | $24 | 0.00% | −6−13.3% | Reduced |
| JPMorgan Chase & Co | 5 | $3 | 0.00% | +5 | New |
| Citadel Advisors LLC | 0 | $0 | 0.00% | −23,173−100.0% | Sold out |
| Claro Advisors LLC | 0 | $0 | 0.00% | −17,305−100.0% | Sold out |
| Renaissance Technologies LLC | 0 | $0 | 0.00% | −14,904−100.0% | Sold out |
| Morgan Stanley | 0 | $0 | 0.00% | −8,000−100.0% | Sold out |